Overexpression of ICSBP inhibits bcr-abl induced myeloproliferative disorder

被引：0
作者：
Hao, SX [1 ]
Ren, R [1 ]
机构：
[1] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
375
引用
收藏
页码：92A / 92A
页数：1
相关论文
共 50 条
[21]   Biology of BCR-ABL [J].
Chopra, R ;
Pu, QQ ;
Elefanty, AG .
BLOOD REVIEWS, 1999, 13 (04) :211-229
[22]   Paradoxical reversal of Hsp90 inhibitor-induced BCR-ABL degradation by the BCR-ABL inhibitor [J].
Tsukahara, F ;
Maru, Y .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 :90P-90P
[23]   Can Activation Induced Cytidine Deaminase Lead to Genetic Instability in Bcr-Abl Negative Myeloproliferative Neoplasms? [J].
Dermenci, Hasan ;
Daglar, Aynur ;
Akadam, Basak Peker ;
Hancer, Veysel Sabri ;
Gelmez, Yusuf ;
Aktan, Melih ;
Nalcaci, Meliha ;
Yavuz, Akif S. .
BLOOD, 2012, 120 (21)
[24]   Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders [J].
Reiter, Andreas ;
Walz, Christoph ;
Cross, Nicholas C. P. .
CURRENT DRUG TARGETS, 2007, 8 (02) :205-216
[25]   Clonal Competition Between JAK2 and BCR-ABL in Myeloproliferative Neoplasm [J].
Salk, Gabriel ;
Mangala, Yashvin Onkarappa ;
Onukogu, Ifeanyichukwu David ;
Meleveedu, Kapil .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 :S384-S384
[26]   Thiol/Disulfide Balance in Older Patients with BCR-ABL Negative Myeloproliferative Neoplasms [J].
Koyuncu, Mahmut B. ;
Cavusoglu, Cagatay ;
Basir, Hakan ;
Ilgan, Mustafa ;
Ucar, Mehmet A. ;
Akdeniz, Aydan ;
Tombak, Anil ;
Tiftik, Eyup N. ;
Temel, Gulhan O. ;
Neselioglu, Salim ;
Erel, Ozcan .
CLINICAL LABORATORY, 2021, 67 (12) :2700-2706
[27]   Therapeutic potential of Axl blockade in BCR-ABL negative myeloproliferative neoplasms (MPN) [J].
Beitzen-Heineke, A. ;
Ben Batalla, I ;
Paesler, S. ;
Gensch, V ;
Schafhausen, P. ;
von Amsberg, G. ;
Riecken, K. ;
Fischer, T. ;
Pantel, K. ;
Bokemeyer, C. ;
Loges, S. .
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 :27-27
[28]   Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN) [J].
Beitzen-Heineke, Antonia ;
Ben Batalla, Isabel ;
Berenbrok, Nikolaus ;
Paesler, Sarina ;
Gensch, Victoria ;
von Amsberg, Gunhild ;
Schafhausen, Philippe ;
Riecken, Kristoffer ;
Fischer, Thomas ;
Pantel, Klaus ;
Bokemeyer, Carsten ;
Loges, Sonja .
BLOOD, 2018, 132
[29]   Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders [J].
Mesa, Ruben A. .
BIOLOGICS-TARGETS & THERAPY, 2007, 1 (02) :129-138
[30]   Response: Too much BCR-ABL to live on, but too little BCR-ABL to die on? [J].
Burchert, Andreas ;
Neubauer, Andreas ;
Hochhaus, Andreas .
BLOOD, 2012, 119 (12) :2965-2966
12345